Propranolol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1967
- First approval year
- 1967
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Propranolol
- Molecular weight
- 259.35
- Structure (SMILES)
- CC(C)NCC(O)COc1cccc2ccccc12
- .beta.-propranolol
- (±)-Propranolol
- ay 64043
- ay 64043 free base
- AY-64043 free base
- AY-64043-
- beta propranolol
- betalong
- Betalong
- dl propranolol
- Dl-propranolol
- euprovasin
- Euprovasin
- inderide 40 25
- inderide 80 25
- Inderide-40/25
- Inderide-80/25
- innopran xl
- INNOPRAN XL
- propranolol
- Propranolol
- Propranolol [INN]
- Propranolol [MI]
- Propranolol [VANDF]
- Propranolol [WHO-DD]
And 10 more, listed on the interactive page.
- ATC classification codes
- C07AA05
Sources for recorded values
- CAS registry numbers
- 525-66-6
- ChEMBL ID
- CHEMBL27
- InChIKey
- AQHHHDLHHXJYJD-UHFFFAOYSA-N
- PubChem compound IDs
- 4946
- FDA ingredient codes (UNII)
- 9Y8NXQ24VQ
- 8787
- 82084
- Applicant
- WYETH PHARMS
- Approval date
- 13 Nov 1967
- Application number
- NDA016418
- Status
- Authorised
- Status date
- 23 Apr 2014
- Authorisation date
- 23 Apr 2014
- Approved indications
- Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: Life- or function-threatening haemangioma, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures, Haemangioma with a risk of permanent scars or disfigurement. It is to be initiated in infants aged 5 weeks to 5 months.
- Product number
- EMEA/H/C/002621
- Authorisation holder
- Pierre Fabre Medicament
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Hemangioma
European medicines record
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- propranolol
- Type
- Synthetic organic
- Drug name stem
- -olol
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- β3-adrenoceptor
- Gene symbol
- ADRB3
- Protein identifier
- P13945
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Beta-1 adrenergic receptor antagonist
- Action type
- Antagonist
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist
- Action type
- Antagonist
- Target
- Beta-2 adrenergic receptor
- Action type
- Antagonist
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- ADRB1
- Protein identifier
- P08588
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- ADRB3
- Protein identifier
- P13945
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Hypertension
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Wounds and Injuries
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Hypertension, Portal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000666
- Subject identifier
- D006975
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Liver Cirrhosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001422
- Subject identifier
- D008103
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Child Development Disorders, Pervasive
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003756
- Subject identifier
- D002659
- Condition
- Heart Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003777
- Subject identifier
- D006331
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003860
- Subject identifier
- D010190
- Condition
- Osteoporosis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003882
- Subject identifier
- D010024
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
And 51 more, listed on the interactive page.
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000558
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000666
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000712
- Condition identifier
- EFO_0000756
- Condition identifier
- EFO_0001358
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001422
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001425
- Condition identifier
- EFO_0002610
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003015
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003756
- Condition identifier
- EFO_0003758
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003882
- Condition identifier
- EFO_0003895
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003913
- Condition identifier
- EFO_0003918
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003968
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004142
- Highest recorded phase
- 3
And 153 more, listed on the interactive page.
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Event
- altered state of consciousness
- Reports
- 57
- Reporting signal score
- 62.4745
- Event
- atrioventricular block first degree
- Reports
- 36
- Reporting signal score
- 71.6364
- Event
- bradycardia
- Reports
- 461
- Reporting signal score
- 904.611
- Event
- bronchial hyperreactivity
- Reports
- 25
- Reporting signal score
- 78.0191
- Event
- cardiac arrest
- Reports
- 185
- Reporting signal score
- 347.761
- Event
- cardio-respiratory arrest
- Reports
- 46
- Reporting signal score
- 75.2536
- Event
- cardiogenic shock
- Reports
- 128
- Reporting signal score
- 326.158
- Event
- circulatory collapse
- Reports
- 93
- Reporting signal score
- 180.65
- Event
- coma
- Reports
- 182
- Reporting signal score
- 286.93
- Event
- coma scale abnormal
- Reports
- 31
- Reporting signal score
- 63.7103
- Event
- cyanosis
- Reports
- 48
- Reporting signal score
- 62.3865
- Event
- depressed level of consciousness
- Reports
- 83
- Reporting signal score
- 73.8373
- Event
- drug interaction
- Reports
- 195
- Reporting signal score
- 86.7865
- Event
- drug intolerance
- Reports
- 118
- Reporting signal score
- 65.198
- Event
- electrocardiogram qrs complex prolonged
- Reports
- 38
- Reporting signal score
- 75.2521
- Event
- electrocardiogram qt prolonged
- Reports
- 87
- Reporting signal score
- 77.9807
- Event
- granulomatous rosacea
- Reports
- 13
- Reporting signal score
- 65.3949
- Event
- heart rate decreased
- Reports
- 82
- Reporting signal score
- 108.901
- Event
- hyperkalaemia
- Reports
- 83
- Reporting signal score
- 77.2245
- Event
- hypoglycaemia
- Reports
- 193
- Reporting signal score
- 290.029
- Event
- hypoglycaemic seizure
- Reports
- 36
- Reporting signal score
- 136.278
- Event
- hypotension
- Reports
- 518
- Reporting signal score
- 606.068
- Event
- migraine
- Reports
- 100
- Reporting signal score
- 85.3246
- Event
- peripheral coldness
- Reports
- 56
- Reporting signal score
- 103.41
- Event
- poisoning deliberate
- Reports
- 85
- Reporting signal score
- 203.917
And 9 more, listed on the interactive page.
- NCT00000197
- NCT00158132
- NCT00688805
- NCT00830362
- NCT01822587
- NCT01978457
- NCT00000492
- NCT00000493
- NCT00069355
- NCT00356187
- NCT01007084
- NCT00093860
- NCT00236561
- NCT00772031
- NCT01080677
- NCT05851781
- NCT06361446
- NCT00315913
- NCT04741698
- NCT00390546
- NCT00465608
- NCT00611871
- NCT01127568
- NCT01239173
- NCT01349439
And 96 more, listed on the interactive page.
- Dose
- 40mg
- Route
- Oral
- How often
- Twice daily
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 2
- Polar surface area
- 41.49
- Calculated partition coefficient (ALogP)
- 2.58
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 19
- Molecular formula
- C16H21NO2
- Monoisotopic mass
- 259.157228913
- Natural product
- Yes
- Recorded assays
- 4,028
- Active assays
- 190
- Confirmatory
- Other
- Adrenergic beta-Antagonists
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
These details could not be displayed.
Related records
Trials (288)
- ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
- ¹³C-Methacetin Breath Test (MBT) Methodology Study
- 8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding
- 8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis
- A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy
- A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
- A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol
- a Prospective Cohort Study for Propranolol Treatment in Retinopathy of Prematurity
- A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol
- A Randomized Trial of GVS Alone vs. Propranolol
- A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease
- A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
- A Study of Continuous Blood Pressure Monitoring in Healthy Participants
- A Study of Continuous Heart Rate Monitoring in Healthy Participants
- A Study of Lasmiditan and Propranolol in Healthy Participants
- A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
- A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State
- A Study of Propranolol to Treat Kaposi Sarcoma
- A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine
Approved for (1)
In development for (67)
- Acute stress disorder Phase 2
- Age-related macular degeneration Phase 2
- Angiosarcoma Phase 2
- Anxiety Phase 2
- Anxiety disorder Phase 2
- Aphasia Early phase 1
- Asthma Phase 2
- Autism spectrum disorder Early phase 1
- Brain injury Phase 3
- Breast cancer Phase 2
- Burn Phase 2
- Cancer Phase 1
- Cardiac rhythm disease Phase 3
- Cerebral cavernous malformation Phase 2
- Chronic obstructive pulmonary disease Phase 1
- Cirrhosis of liver Phase 3
- Cocaine dependence Phase 2
- Colorectal neoplasm Phase 3
- Coronary artery disorder Phase 3
- Digestive system neoplasm Phase 2
Other linked conditions (3)
- Autism
- Capillary hemangioma
- Cervical cancer